Sagimet Biosciences Inc. SGMT 深 沪
已收盘 08-01 16:00:00 美东时间
8.25
-0.440
-5.06%
华盛通- 最 高8.81
- 今 开8.60
- 成交量 82.69万股
- 最 低 7.98
- 昨 收 8.69
- 总市值 2.66亿
- 52周最高 11.41
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.73
- 委 比 40.18%
- 总股本 3219.53万
- 历史最高 20.71
- 量 比 0.98
- 振 幅 9.55%
- 历史最低 1.73
- 每 手 1
- 风险率 2.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Canaccord Genuity Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $28
Canaccord Genuity analyst Edward Nash initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces Price Target of $28.
07-24 18:19
美股牛股 | 乌龙制药暴涨近52%！CureVac升近38%，获BioNTech以12.5亿美元收购
乌龙制药暴涨近52%！研发泌尿系统治疗新药取得突破性进展；CureVac隔夜升近38%，获BioNTech以12.5亿美元收购>>
06-13 19:33
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
Sagimet Biosciences will host a virtual KOL event on June 16, 2025, featuring Neal Bhatia, MD, to discuss Phase 3 trial results of denifanstat for moderate to severe acne vulgaris in China. Denifanstat, a once-daily oral FASN inhibitor, met all endpoints versus placebo and was well-tolerated, highlighting FASN inhibition as a novel acne treatment mechanism. Sagimet is also advancing TVB-3567, a second oral FASN inhibitor, into Phase 1 trials for ...
06-09 11:00
美股牛股 | 稳定币巨头Circle上市首日受热捧，飙涨168.5%；科技股Nebius Group涨超17%
稳定币巨头Circle上市首日受热捧，飙涨168.5%市值超180亿美元；科技股Nebius Group涨超17%，公司获10亿美元大额融资>>
06-06 19:26
Reported Earlier, Ascletis' Denifanstat, Licensed From Sagimet, Meets All Endpoints In Phase III Trial For Moderate To Severe Acne
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary
06-04 14:36
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Denifanstat, an oral FASN inhibitor, met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne, demonstrating significant reductions in lesion counts and inflammation. It was well-tolerated with no serious adverse events. Sagimet Biosciences has initiated a Phase 1 trial for another FASN inhibitor, TVB-3567, targeting acne in the U.S. These results highlight FASN inhibition as a novel and promising approach for treati...
06-04 09:00
歌礼制药-B：同类首创、每日一次口服FASN抑制剂地尼法司他(ASC40) 痤疮III期试验达到所有终点
歌礼制药-B(01672)发布公告，同类首创(first-in-class)、每日...
06-04 07:11
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
03-14 09:45
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom
Sagimet Biosciences, Inc. Class A (SGMT) has disclosed a new risk, in the Techn...
03-13 14:01
美股大行评级 | 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106863358302064640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元</p> <p>• HC Wainwright & Co.：维持LifeMD(LFMD)"买入"评级，目
03-13 09:38
